KYORIN Pharmaceutical Co., Ltd.
Notice Regarding Introduction of Delegated Executive Officer System and Executive Officer Personnel Changes
Introduction of delegated executive officer system effective April 1, 2026, and implementation of executive officer personnel changes. CEO Yutaka Ogihara continues in his role.
Key Figures
- Delegated Executive Officer System Introduction Date: 2026-04-01
- Representative Director President CEO: Yutaka Ogihara (Continuing)
- Number of Senior Executive Officers (Delegated Type) Appointed: 4
AI要約
About the Introduction of the Delegated Executive Officer System
Kyorin Pharmaceutical Co., Ltd. will introduce a delegated executive officer system in addition to the existing employment-type executive officer system, effective April 1, 2026, aiming to strengthen corporate governance. Delegated executive officers will be limited to senior executive officers and above. Directors may concurrently serve as executive officers, promoting the separation of decision-making and supervisory functions from business execution functions, with the goal of enhancing management soundness and transparency.
Regarding Executive Officer Personnel Changes
In the personnel changes effective April 1, 2026, Yutaka Ogihara will continue as Representative Director President CEO. Directors Michio Onoda and Yasushi Kurose will be appointed as senior executive officers. Takaaki Kaji, Noriaki Tamura, Junichi Ishiyama, and Takeo Uehara will be promoted to senior executive officers as delegated executive officers and appointed heads of their respective divisions. Additionally, new employment-type executive officers will be appointed, and some changes made to their responsibilities to strengthen the organizational structure.
Kyorin Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
